Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2016 Jan 6:16:5.
doi: 10.1186/s12885-015-2040-0.

Population attributable risks of modifiable reproductive factors for breast and ovarian cancers in Korea

Boyoung Park  1   2 , Sohee Park  3   4 , Hai-Rim Shin  5 , Aesun Shin  6   7 , Yohwan Yeo  8 , Ji-Yeob Choi  9 , Kyu-Won Jung  10 , Byoung-Gie Kim  11 , Yong-Man Kim  12 , Dong-Young Noh  13 , Sei-Hyun Ahn  14 , Jae Weon Kim  15 , Sokbom Kang  16 , Jae Hoon Kim  17 , Tae Jin Kim  18 , Daehee Kang  19   20   21 , Keun-Young Yoo  22 , Sue K Park  23   24   25
Affiliations
Meta-Analysis

Population attributable risks of modifiable reproductive factors for breast and ovarian cancers in Korea

Boyoung Park et al. BMC Cancer. .

Erratum in

Abstract

Background: Breast and ovarian cancers are predominant female cancers with increasing prevalence. The purpose of this study was to estimate the population attributable risks (PARs) of breast and ovarian cancer occurrence based on the relative risks (RRs) of modifiable reproductive factors and population-specific exposure prevalence.

Methods: The PAR was calculated by using the 1990 standardized prevalence rates, the 2010 national cancer incidence with a 20 year lag period, the meta-analyzed RRs from studies conducted in the Korean population for breast cancer, and the meta-analyzed RRs from a Korean epithelial ovarian cancer study and a prior meta-analysis, and ovarian cancer cohort results up to 2012. For oral contraceptive and hormone replacement therapy use, we did not consider lag period.

Results: The summary PARs for modifiable reproductive factors were 16.7% (95% CI 15.8-17.6) for breast cancer (2404 cases) and 81.9% (95% CI 55.0-100.0) for ovarian cancer (1579 cases). The modifiable reproductive factors included pregnancy/age at first birth (8.0%), total period of breastfeeding (3.1%), oral contraceptive use (5.3%), and hormone replacement therapy use (0.3%) for breast cancer and included breastfeeding experience (2.9%), pregnancy (1.2%), tubal ligation (24.5%), and oral contraceptive use (53.3%) for ovarian cancer.

Conclusions: Despite inherent uncertainties in the risk factors for breast and ovarian cancers, we suggest that appropriate long-term control of modifiable reproductive factors could reduce breast and ovarian cancer incidences and their related burdens by 16.7% and 81.9%, respectively.

PubMed Disclaimer

References

    1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer Journal international du cancer. 2010;127(12):2893–917. doi: 10.1002/ijc.25516. - DOI - PubMed
    1. Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol. 2001;2(3):133–40. doi: 10.1016/S1470-2045(00)00254-0. - DOI - PubMed
    1. Hunn J, Rodriguez GC. Ovarian cancer: etiology, risk factors, and epidemiology. Clin Obstet Gynecol. 2012;55(1):3–23. doi: 10.1097/GRF.0b013e31824b4611. - DOI - PubMed
    1. Cogliano V, Grosse Y, Baan R, Straif K, Secretan B, El Ghissassi F. Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol. 2005;6(8):552–3. doi: 10.1016/S1470-2045(05)70273-4. - DOI - PubMed
    1. Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev. 1993;15(1):17–35. - PubMed

Publication types

Substances